by Alison Bass | Apr 13, 2016 | antidepressants, antipsychotic drugs, clinical trials, conflicts of interest, drug marketing, FDA, pharmaceutical industry, prostitution, sex work
After my first nonfiction book, Side Effects: A Prosecutor, a Whistleblower and a Bestselling Antidepressant on Trial, was published, a number of readers told me that the book would make a great movie. (It’s written as a narrative and tells the true story of two...
by Alison Bass | Sep 5, 2012 | antidepressants, clinical trials, conflicts of interest, drug marketing, ghostwriting, pharmaceutical industry, scientific journal retractions, scientific misconduct
I just learned that Dr. Martin Keller, principal investigator of the controversial Paxil study 329, has retired from his position as a professor of psychiatry at Brown University — see here. As Pharmalot notes, Keller quietly retired June 30 in the midst of an...
by Alison Bass | Sep 4, 2012 | antidepressants, clinical trials, conflicts of interest, drug marketing, ghostwriting, National Institutes of Health, pharmaceutical industry, scientific journal retractions, scientific misconduct, university industry collaboration
In the wake of GlaxoSmithKline’s record-breaking $3 billion settlement with the U.S. Department of Justice, a number of psychiatrists and researchers have redoubled their efforts to get Paxil study 329 retracted. As mentioned here and in other news accounts, the...
by Alison Bass | Aug 7, 2012 | antidepressants, clinical trials, National Institutes of Health, pharmaceutical industry, scientific journal retractions, scientific misconduct, university industry collaboration
The Chronicle of Higher Education this week ponders why various universities have taken no action against the academic researchers who co-authored the notorious Paxil study that formed the crux of GlaxoSmithKline’s recent $3 billion settlement with the...
by Alison Bass | Jul 3, 2012 | antidepressants, antipsychotic drugs, clinical trials, drug marketing, patient care, pharmaceutical industry, scientific journal retractions, scientific misconduct, suicide rates, whistleblowing
I was glad to see that the New York Times’ reporters covering GlaxoSmithKline’s $3 billion settlement tipped their hat to former New York Attorney General Eliot Spitzer. After all, it was his crew and specifically a pioneering attorney by the name of Rose...
by Alison Bass | Jun 7, 2012 | biotech industry, clinical trials, conflicts of interest, pharmaceutical industry, Uncategorized
Senator Charles Grassley is upping the ante on the controversy surrounding the Vertex pharmaceutical executives who cashed in on overstated clinical trial data — see my blog from last week. According to The Boston Globe, which broke the Vertex story, Grassley...